四环生物
(000518)
| 流通市值：26.77亿 | | | 总市值：26.77亿 |
| 流通股本：10.30亿 | | | 总股本：10.30亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 155,994,341.01 | 105,808,385.29 | 56,398,850.85 | 235,419,049.03 |
| 营业收入 | 155,994,341.01 | 105,808,385.29 | 56,398,850.85 | 235,419,049.03 |
| 利息收入 | 0 | 0 | 0 | 0 |
| 已赚保费 | 0 | 0 | 0 | 0 |
| 手续费及佣金收入 | 0 | 0 | 0 | 0 |
| 二、营业总成本 | 171,712,575.42 | 115,688,351.27 | 56,979,130.03 | 287,686,024.21 |
| 营业成本 | 48,586,241.13 | 35,115,239.08 | 16,048,349.26 | 71,187,239.37 |
| 利息支出 | 0 | 0 | 0 | 0 |
| 手续费及佣金支出 | 0 | 0 | 0 | 0 |
| 退保金 | 0 | 0 | 0 | 0 |
| 赔付支出净额 | 0 | 0 | 0 | 0 |
| 提取保险合同准备金净额 | 0 | 0 | 0 | 0 |
| 保单红利支出 | 0 | 0 | 0 | 0 |
| 分保费用 | 0 | 0 | 0 | 0 |
| 税金及附加 | 1,031,776.37 | 778,740.24 | 230,286.5 | 1,393,778.22 |
| 销售费用 | 56,857,787.86 | 35,319,052.8 | 17,711,806.65 | 116,564,330.67 |
| 管理费用 | 42,952,796.62 | 29,120,287.1 | 15,542,257.5 | 67,006,930.52 |
| 研发费用 | 20,697,253.25 | 14,278,997.48 | 6,903,522.01 | 29,150,204.8 |
| 财务费用 | 1,586,720.19 | 1,076,034.57 | 542,908.11 | 2,383,540.63 |
| 其中:利息费用 | 1,128,624.62 | 386,058.16 | 565,110.54 | 2,462,301.36 |
| 其中:利息收入 | 5,361.78 | 5,115.61 | 7,624.1 | 44,981.97 |
| 加:公允价值变动收益 | 14,647 | 5,858.8 | 22,702.85 | -24,899.9 |
| 加:投资收益 | 0 | 0 | 34,744.67 | 1,752,493.89 |
| 净敞口套期收益 | 0 | 0 | 0 | 0 |
| 汇兑收益 | 0 | 0 | 0 | 0 |
| 资产处置收益 | 0 | 0 | 0 | 0 |
| 资产减值损失(新) | 84,402.24 | 0 | 0 | -19,777,233.74 |
| 信用减值损失(新) | 0 | -512,164.45 | -3,563,007.96 | -6,352,144.77 |
| 其他收益 | 13,880.43 | 13,744.33 | 37,537.38 | 117,044.98 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -15,605,304.74 | -10,372,527.3 | -4,048,302.24 | -76,551,714.72 |
| 加:营业外收入 | 3,328,234.09 | 21,124.91 | 20,824.91 | 47,626.42 |
| 减:营业外支出 | 3,255,350.95 | 1,291,624 | 30,000 | 2,921,337.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -15,532,421.6 | -11,643,026.39 | -4,057,477.33 | -79,425,425.33 |
| 减:所得税费用 | 0 | 0 | -827,259.17 | 989,435.97 |
| 六、净利润 | -15,532,421.6 | -11,643,026.39 | -3,230,218.16 | -80,414,861.3 |
| 持续经营净利润 | -15,532,421.6 | -11,643,026.39 | -3,230,218.16 | -80,414,861.3 |
| 终止经营净利润 | 0 | 0 | 0 | 0 |
| 归属于母公司股东的净利润 | -14,617,155.78 | -11,058,090.16 | -2,967,209.29 | -75,269,896.35 |
| 少数股东损益 | -915,265.82 | -584,936.23 | -263,008.87 | -5,144,964.95 |
| (一)基本每股收益 | -0.01 | -0.01 | 0 | -0.07 |
| (二)稀释每股收益 | -0.01 | -0.01 | 0 | -0.07 |
| 八、其他综合收益 | 0 | 0 | 0 | -300,000 |
| 归属于母公司股东的其他综合收益 | 0 | 0 | 0 | -264,000 |
| 九、综合收益总额 | -15,532,421.6 | -11,643,026.39 | -3,230,218.16 | -80,714,861.3 |
| 归属于母公司股东的综合收益总额 | -14,617,155.78 | -11,058,090.16 | -2,967,209.29 | -75,533,896.35 |
| 归属于少数股东的综合收益总额 | -915,265.82 | -584,936.23 | -263,008.87 | -5,180,964.95 |
| 公告日期 | 2024-10-30 | 2024-08-31 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |